Tokyo Tape
Sign in
← GNI Group

Quarterly report · Q3

2160.TEDINET S100PN1P
Period2022-01-01 → 2022-09-30
Filed2022-11-14
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 62
MetricValuePeriodScopeSource row
Revenue¥12.8bn2022-01-01 → 2022-09-30Cons.Revenue IFRS
Revenue¥4.6bn2022-07-01 → 2022-09-30dCons.Revenue IFRS
Revenue¥12.7bn2021-01-01 → 2021-12-31Cons.Revenue IFRS (5-year summary)
Revenue¥9.5bn2021-01-01 → 2021-09-30Cons.Revenue IFRS
Revenue¥3.1bn2021-07-01 → 2021-09-30dCons.Revenue IFRS
Operating income¥1.5bn2022-01-01 → 2022-09-30Cons.Operating profit loss IFRS
Operating income¥490m2022-07-01 → 2022-09-30dCons.Operating profit loss IFRS
Operating income¥2.0bn2021-01-01 → 2021-09-30Cons.Operating profit loss IFRS
Operating income¥505m2021-07-01 → 2021-09-30dCons.Operating profit loss IFRS
Profit before tax¥1.2bn2022-01-01 → 2022-09-30Cons.Profit loss before tax IFRS
Profit before tax¥433m2022-07-01 → 2022-09-30dCons.Profit loss before tax IFRS
Profit before tax¥1.1bn2021-01-01 → 2021-12-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥1.6bn2021-01-01 → 2021-09-30Cons.Profit loss before tax IFRS
Profit before tax¥371m2021-07-01 → 2021-09-30dCons.Profit loss before tax IFRS
Net income (owners)¥1.1bn2022-01-01 → 2022-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥400m2022-07-01 → 2022-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥1.1bn2021-01-01 → 2021-12-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥1.3bn2021-01-01 → 2021-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥353m2021-07-01 → 2021-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income¥324m2022-01-01 → 2022-09-30Cons.Profit loss IFRS
Net income¥126m2022-07-01 → 2022-09-30dCons.Profit loss IFRS
Net income¥55m2021-01-01 → 2021-12-31Cons.Profit loss IFRS (5-year summary)
Net income¥875m2021-01-01 → 2021-09-30Cons.Profit loss IFRS
Net income¥130m2021-07-01 → 2021-09-30dCons.Profit loss IFRS
Total assets¥36.5bnat 2022-09-30Cons.Assets IFRS
Total assets¥30.3bnat 2021-12-31Cons.Assets IFRS
Total assets¥29.8bnat 2021-09-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥14.4bnat 2022-09-30Cons.Liabilities IFRS
Total liabilities¥11.0bnat 2021-12-31Cons.Liabilities IFRS
Net assets / equity¥22.0bnat 2022-09-30Cons.Equity IFRS
Net assets / equity¥19.3bnat 2021-12-31Cons.Equity IFRS
Net assets / equity¥19.4bnat 2021-09-30Cons.Equity IFRS
Net assets / equity¥12.8bnat 2020-12-31dCons.Equity IFRS
Equity (owners)¥22.9bnat 2022-09-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥18.9bnat 2021-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥18.5bnat 2021-09-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥12.7bnat 2022-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥14.4bnat 2021-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥13.9bnat 2021-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥10.3bnat 2020-12-31dCons.Cash and cash equivalents IFRS
Operating cash flow−¥163m2022-01-01 → 2022-09-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥552m2021-01-01 → 2021-12-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥755m2021-01-01 → 2021-09-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥2.9bn2022-01-01 → 2022-09-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥261m2021-01-01 → 2021-12-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥884m2021-01-01 → 2021-09-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥299m2022-01-01 → 2022-09-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow¥2.9bn2021-01-01 → 2021-12-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow¥3.2bn2021-01-01 → 2021-09-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥22.672022-01-01 → 2022-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥8.422022-07-01 → 2022-09-30dCons.Basic earnings loss per share IFRS
EPS (basic)¥22.722021-01-01 → 2021-12-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥27.692021-01-01 → 2021-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥7.442021-07-01 → 2021-09-30dCons.Basic earnings loss per share IFRS
EPS (diluted)¥22.462022-01-01 → 2022-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥8.282022-07-01 → 2022-09-30dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥22.082021-01-01 → 2021-12-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥26.872021-01-01 → 2021-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥7.322021-07-01 → 2021-09-30dCons.Diluted earnings loss per share IFRS
Equity ratio62.8%at 2022-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio62.3%at 2021-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio62.1%at 2021-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 26
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-01-01 → 2022-09-30−¥38m
Reconciling Itemsreconcilingrevenue intersegment2022-01-01 → 2022-09-30−¥38m
jpcrp040300-q3r_E05712-000Medical Devicereportable segmentrevenue2022-01-01 → 2022-09-30¥1.8bn
jpcrp040300-q3r_E05712-000Medical Devicereportable segmentrevenue external2022-01-01 → 2022-09-30¥1.7bn
jpcrp040300-q3r_E05712-000Medical Devicereportable segmentrevenue intersegment2022-01-01 → 2022-09-30¥38m
jpcrp040300-q3r_E05712-000Medical Devicereportable segmentsegment profit2022-01-01 → 2022-09-30¥699m
jpcrp040300-q3r_E05712-000Pharmaceuticalreportable segmentrevenue2022-01-01 → 2022-09-30¥11.0bn
jpcrp040300-q3r_E05712-000Pharmaceuticalreportable segmentrevenue external2022-01-01 → 2022-09-30¥11.0bn
jpcrp040300-q3r_E05712-000Pharmaceuticalreportable segmentsegment profit2022-01-01 → 2022-09-30¥796m
—segment totalrevenue2022-01-01 → 2022-09-30¥12.8bn
—segment totalrevenue external2022-01-01 → 2022-09-30¥12.8bn
—segment totalrevenue intersegment2022-01-01 → 2022-09-30¥38m
—segment totalsegment profit2022-01-01 → 2022-09-30¥1.5bn
Reconciling Itemsreconcilingrevenue2021-01-01 → 2021-09-30−¥35m
Reconciling Itemsreconcilingrevenue intersegment2021-01-01 → 2021-09-30−¥35m
jpcrp040300-q3r_E05712-000Medical Devicereportable segmentrevenue2021-01-01 → 2021-09-30¥1.5bn
jpcrp040300-q3r_E05712-000Medical Devicereportable segmentrevenue external2021-01-01 → 2021-09-30¥1.5bn
jpcrp040300-q3r_E05712-000Medical Devicereportable segmentrevenue intersegment2021-01-01 → 2021-09-30¥35m
jpcrp040300-q3r_E05712-000Medical Devicereportable segmentsegment profit2021-01-01 → 2021-09-30¥547m
jpcrp040300-q3r_E05712-000Pharmaceuticalreportable segmentrevenue2021-01-01 → 2021-09-30¥8.1bn
jpcrp040300-q3r_E05712-000Pharmaceuticalreportable segmentrevenue external2021-01-01 → 2021-09-30¥8.1bn
jpcrp040300-q3r_E05712-000Pharmaceuticalreportable segmentsegment profit2021-01-01 → 2021-09-30¥1.4bn
—segment totalrevenue2021-01-01 → 2021-09-30¥9.6bn
—segment totalrevenue external2021-01-01 → 2021-09-30¥9.5bn
—segment totalrevenue intersegment2021-01-01 → 2021-09-30¥35m
—segment totalsegment profit2021-01-01 → 2021-09-30¥2.0bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 716
ItemContextValueUnit
Repayments of long term borrowings fin cf IFRSPrior1YTDDuration-75000000JPY
Repayments of long term borrowings fin cf IFRSCurrentYTDDuration－JPY
Proceeds from exercise of share acquisition rights fin cf IFRSPrior1YTDDuration1319377000JPY
Proceeds from exercise of share acquisition rights fin cf IFRSCurrentYTDDuration－JPY
Proceeds from issuance of share acquisition rights fin cf IFRSPrior1YTDDuration86425000JPY
Proceeds from issuance of share acquisition rights fin cf IFRSCurrentYTDDuration－JPY
Capital contribution from non controlling interests fin cf IFRSPrior1YTDDuration2985125000JPY
Capital contribution from non controlling interests fin cf IFRSCurrentYTDDuration－JPY
Repayments of lease obligations fin cf IFRSPrior1YTDDuration-70028000JPY
Repayments of lease obligations fin cf IFRSCurrentYTDDuration-98520000JPY
Payments for purchase of treasury shares fin cf IFRSPrior1YTDDuration-95000JPY
Payments for purchase of treasury shares fin cf IFRSCurrentYTDDuration－JPY
Refund from non controlling interest fin cf IFRSPrior1YTDDuration-524447000JPY
Refund from non controlling interest fin cf IFRSCurrentYTDDuration－JPY
Dividends paid fin cf IFRSPrior1YTDDuration-150838000JPY
Dividends paid fin cf IFRSCurrentYTDDuration－JPY
Other fin cf IFRSPrior1YTDDuration-25111000JPY
Other fin cf IFRSCurrentYTDDuration-760000JPY
Net cash provided by used in financing activities IFRSPrior1YTDDuration3176682000JPY
Net cash provided by used in financing activities IFRSCurrentYTDDuration-299280000JPY
Effect of exchange rate changes on cash and cash equivalents IFRSPrior1YTDDuration575064000JPY
Effect of exchange rate changes on cash and cash equivalents IFRSCurrentYTDDuration1741793000JPY
Net increase decrease in cash and cash equivalents IFRSPrior1YTDDuration3622810000JPY
Net increase decrease in cash and cash equivalents IFRSCurrentYTDDuration-1629920000JPY
Cash and cash equivalents IFRSPrior2YearInstant10322664000JPY
Cash and cash equivalents IFRSPrior1YearInstant14352133000JPY
Cash and cash equivalents IFRSPrior1QuarterInstant13945474000JPY
Cash and cash equivalents IFRSCurrentQuarterInstant12722213000JPY
Revenue from external customers IFRSPrior1YTDDuration_jpcrp040300-q3r_E05712-000PharmaceuticalReportableSegmentMember8064969000JPY
Revenue from external customers IFRSPrior1YTDDuration_jpcrp040300-q3r_E05712-000MedicalDeviceReportableSegmentMember1471744000JPY
Revenue from external customers IFRSPrior1YTDDuration_ReportableSegmentsMember9536714000JPY
Revenue from external customers IFRSPrior1YTDDuration_ReconcilingItemsMember－JPY
Revenue from external customers IFRSPrior1YTDDuration9536714000JPY
Intersegment revenue IFRSPrior1YTDDuration_jpcrp040300-q3r_E05712-000PharmaceuticalReportableSegmentMember－JPY
Intersegment revenue IFRSPrior1YTDDuration_jpcrp040300-q3r_E05712-000MedicalDeviceReportableSegmentMember34995000JPY
Intersegment revenue IFRSPrior1YTDDuration_ReportableSegmentsMember34995000JPY
Intersegment revenue IFRSPrior1YTDDuration_ReconcilingItemsMember-34995000JPY
Intersegment revenue IFRSPrior1YTDDuration－JPY
Revenue IFRSPrior1YTDDuration_jpcrp040300-q3r_E05712-000PharmaceuticalReportableSegmentMember8064969000JPY
Revenue IFRSPrior1YTDDuration_jpcrp040300-q3r_E05712-000MedicalDeviceReportableSegmentMember1506740000JPY
Revenue IFRSPrior1YTDDuration_ReportableSegmentsMember9571710000JPY
Revenue IFRSPrior1YTDDuration_ReconcilingItemsMember-34995000JPY
Revenue IFRSPrior1YTDDuration9536714000JPY
Operating profit loss IFRSPrior1YTDDuration_jpcrp040300-q3r_E05712-000PharmaceuticalReportableSegmentMember1413052000JPY
Operating profit loss IFRSPrior1YTDDuration_jpcrp040300-q3r_E05712-000MedicalDeviceReportableSegmentMember547408000JPY
Operating profit loss IFRSPrior1YTDDuration_ReportableSegmentsMember1960461000JPY
Operating profit loss IFRSPrior1YTDDuration_ReconcilingItemsMember－JPY
Operating profit loss IFRSPrior1YTDDuration1960461000JPY
Finance income IFRSPrior1YTDDuration69554000JPY
Finance costs IFRSPrior1YTDDuration461276000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 16 of 16 passed
balance sheet identityconsolidated 2021-12-31pass
balance sheet identityconsolidated 2022-09-30pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2021-01-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2021-07-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-01-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-07-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2021-01-01/2021-09-30pass
statement vs summary · operating cash flowconsolidated 2022-01-01/2022-09-30pass
statement vs summary · revenueconsolidated 2021-01-01/2021-09-30pass
statement vs summary · revenueconsolidated 2021-07-01/2021-09-30pass
statement vs summary · revenueconsolidated 2022-01-01/2022-09-30pass
statement vs summary · revenueconsolidated 2022-07-01/2022-09-30pass
statement vs summary · total assetsconsolidated 2021-12-31pass
statement vs summary · total assetsconsolidated 2022-09-30pass